



The homozygous R504C mutation in MTO1 gene is responsible 
for ONCE syndrome 
Miguel Ángel Martína,b, María Teresa García-Silvaa,c,d, Giulia Barciae, Aitor Delmiroa,b, María 
Elena Rodríguez-Garcíab, Alberto Blázqueza,b, Raquel Francisco-Álvarezf, Elena Martín-
Hernándezc,d, Pilar Quijada-Frailec,d,  Pilar Tejada-Palaciosg, Joaquín Arenasa,b, Cruz Santosf 
and Francisco Martínez-Azorína,b,* 
MAM and MTG-S contributed equally to this work 
 
aCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, E-28041 
Madrid, Spain 
 bLaboratorio de Enfermedades Mitocondriales. Instituto de Investigación Hospital 12 de Octubre 
(i+12), E-28041 Madrid, Spain 
cUnidad de Enfermedades Metabólicas Hereditarias, Hospital 12 de Octubre, E-28041 Madrid, Spain 
dFacultad de Medicina, Universidad Complutense de Madrid (UCM), E-28040 Madrid, Spain 
eDepartment of Genetics, Hôpital Necker-Enfants-Malades, 75015 Paris, France 
fUniversidad Francisco de Vitoria, E-28223 Pozuelo de Alarcón, Madrid, Spain 
gDepartamento de Oftalmología, Hospital 12 de Octubre, E-28041 Madrid, Spain 
 
*Corresponding author: Francisco Martínez-Azorín, Laboratorio de Enfermedades Mitocondriales, 
Instituto de Investigación Hospital 12 de Octubre (i+12), Centro de Actividades Ambulatorias (CAA), 
6ª Planta, Bloque E, Avda. Córdoba s/n, E-28041 Madrid, Spain, Phone: +34 91 779 2784; Fax: +34 
91 390 8544; E-mail: fmartinez@h12o.es  
 
Conflicts of interest  





This work was supported by Spanish Instituto de Salud Carlos III (ISCIII) and European Regional 
Development Fund (ERDF) (grant PI10/00063 and PI14/00790 to F.M-A. and grant PI12/01683 to 





 We report clinical and biochemical finding from three unrelated patients presenting 
ONCE (Optic Neuropathy, Cardiomyopathy and Encephalopathy with lactic acidosis and 
combined OXPHOS deficiency) syndrome. Whole-exome sequencing (WES) of the three patients 
and the healthy sister of one of them were used to identify the carry gene. Clinical and 
biochemical findings were used to filter variants, and molecular, in silico and genetic studies 
were performed to characterize the candidate variants. Mitochondrial DNA (mtDNA) defects 
involving mutations, deletions or depletion were discarded, whereas WES uncovered a double 
homozygous mutation in the MTO1 gene (NM_001123226:c.1510C>T, p.R504C, and c.1669G>A, 
p.V557M) in two of the patients and the homozygous mutation p.R504C in the other. Therefore, 
our data confirm p.R504C as pathogenic mutation responsible of ONCE syndrome, and 











Mitochondrial disorders are a group of syndromes associated with severe dysfunction of oxidative 
phosphorylation (OXPHOS). Cardiomyocytes are one of the major targets of OXPHOS defects due to 
their extremely high demand of energy, and hence, infantile hypertrophic cardiomyopathy is a usual 
clinical feature displayed in many mitochondrial disorders. On the other hand, defects in genes 
involved in the mitochondrial translation machinery are increasingly recognized as a cause of 
OXPHOS diseases. Recently, patients exhibiting hypertrophic cardiomyopathy and lactic acidosis as a 
consequence of a combined respiratory chain deficiency have been found to carry mutations in MTO1 
(MIM#614667) (1, 2) and GTPBP3 (MIM#608536) genes (3). In humans, the MTO1 gene encodes an 
evolutionarily conserved protein which works together with the protein encoded by the GTPBP3 gene 
to catalyze the biosynthesis of 5-taurinomethyl (m5U34) of the wobble uridine base in mt-
tRNALeu(UUR), mt-tRNATrp, mt-tRNAGln, mt-tRNAGlu, and mt-tRNALys (4). This modification is 
important to the accuracy and efficiency of mtDNA translation (5). 
 In the present study, we defined a new clinical subgroup of combined OXPHOS deficiency 10 
(MIM#614702; COXPD10) with optic neuropathy and encephalopathy, that we termed ONCE 
syndrome (Optic Neuropathy, Cardiomyopathy, and Encephalopathy with lactic acidosis and 
combined OXPHOS deficiency). Through WES analysis of three unrelated patients, we identified the 







Material and methods 
Written informed consent was obtained from the patients' parents, and the Ethic Committee of the 
respective institutions approved the studies. 
 Whole-exome sequencing (WES) was performed on genomic DNA obtained from patient 
blood following standard protocol described before (6). Nuclear variants and indels were prioritized 
according to the following criteria: (i) variants that were rare in healthy individuals (allele frequency 
below 0.01) or new (not described within public databases); (ii) variants predicted to modify protein 
function (nonsense, splice site, coding indel, or missense variants); (iii) variants consistent with a 
recessive model of pathogenesis (including homozygous variants or two heterozygous variants present 
in the same gene). Additional indications to prioritize the candidate genes were obtained by using 
predictive software scoring the likelihood for pathogenicity SIFT, Polyphen-2, MutPred and Mutation 
Taster. Sanger sequencing of patients, healthy sister and their parents was performed for candidate 






 Patient 1 (Pt1) is the second child of non-consanguineous, healthy parents from western Spain. 
His older sister is healthy. The patient was born at 42 weeks of gestation of an uneventful pregnancy 
and delivery. During infancy he presented with failure to thrive, developmental delay with axial 
hypotonia, slight ataxia of the trunk and episodes of bronchitis. At 22 months old he was found to have 
a hypertrophic non obstructive cardiomyopathy that was treated with verapamil. At 2 years old his 
developmental delay was more prominent in cognitive areas than motor milestones. Basal laboratory 
test results were normal except for hyperlactacidemia. Visual-evoked potentials and brain MRI 
(magnetic resonance images) were normal. A muscle biopsy showed a significant reduction of 
complex I and IV activities of mitochondrial respiratory chain (MRC) whereas histomorphology was 
normal. Mitochondrial DNA (mtDNA) studies showed absence of deletions and depletion, and the 
whole mtDNA sequencing didn't show any pathological variant (Caucasian haplogroup U5a1b). He 
started a treatment with coenzyme Q10 (CoQ10), L-ascorbic acid (vitamin C), riboflavin (vitamin B2) 
and L-carnitine. Clinical examination at the age of 3 showed little face expressivity and tendency to 
open his mouth and drooling. He had scapula alata and equinovarus feet, his weight was 12.6 kg (-1.6 
SD), his length 90 cm (-2 SD) and his cranial circumference 51.1 cm (median). He was able to walk 
alone and go up and down stairs although clumsily; however, the language was delayed. Liver and 
kidney function test were normal. Serum creatine kinase (CK) was slightly elevated (193 IU/L, normal 
< 130 IU/L), with occasional levels of 367 and 404 IU/L. Lactic acid was mildly elevated  (3.7 mM, 
normal < 2.30 mM), with a lactate/pyruvate ratio of 16 (normal < 20). Other metabolic investigations 
showed increased blood levels of alanine (568 M, normal 170-430M). Abdominal ultrasonography 
showed bilateral cortical kidney hyperechogenicity, which persisted along evolution. Hearing studies 
were normal. Holter record was normal but heart ultrasonography showed hypertrophy of the septum 
and posterior wall of left ventricle with slight tricuspid insufficiency. At 6 years old he started with 
epileptic seizures, initially with complex partial seizures, with repetitive crisis for 2 or 3 seconds 
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during hours, sometimes secondary generalized. Then he was treated with lamotrigine and 
clonazepam. At age of 7, he presented inconstant bilateral ptosis and mental deterioration. EEG 
(electroencephalography) showed generalized polyspikes-waves discharges and photosensitivity. He 
also presented optic atrophy with reduction in visual acuity (10% of normal), that interfered in his 
learning abilities, especially in writing and reading. Brain MRI spectroscopy showed no abnormalities. 
At 11 years old, he presented moderate intellectual disability (IQ of 54), slight ataxia, dysmetria and 
some difficulties to stand up on one foot and stand up from the floor. A new brain MR spectroscopy 
didn’t show abnormalities. Laboratory examinations in cerebrospinal fluid (CSF) showed a slight 
decreased of 5-methyltetrahydrofolate (5-MTHF 29 nmol/l, normal 35-124 nmol/l) and a slight 
increased of homovanillic acid (579 nM, normal 156-410 nM), while the plasma folic acid was normal. 
In addition to previous therapy, he started treatment with folinic acid with subsequent normalization of 
biochemical parameters and a slight improvement of his behavior and scholar performance but without 
major changes in her cognitive status. 
 Currently, at 16 years old, the clinical conditions remain stable. Ophthalmological examination 
revealed several disturbance in distance visual acuity without correction in both eyes (20/200), 
orthophoria in primary position, but divergent exotropia (-2º) with dominant right eye. Fundoscopy 
revealed papillary pallor indicating that he had bilateral papillary atrophy more prominent on right eye 
(Fig. 1a). Optical Coherence Tomography (OCT) showed significant thinning of macular ganglion cell 
layer (Fig. 1b), and thinning of macular and peripapillary retinal nerve fiber layer (RNLF) in both eyes 
(Fig. 1c).    
 Patient 2 (Pt2) is the only child of non-consanguineous parents from southeastern Spain. Her 
maternal grandmother is diabetic and a paternal half-brother is healthy. Pt2 was born of an uneventful 
pregnancy and forceps delivery. The neonatal period and early development were normal. In the 
scholar period she had learning difficulties and developmental delay. At 8 years old, she presented 
intellectual disability, clumsiness and slight fatigability. Laboratory determinations showed elevated 
plasma alanine and hyperlactacidemia (lactic acid levels between 8.9 and 5.7 mM, normal 0.50-2.30 
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mM), while lactic acid in CSF was normal. EEG was normal and brain MRI showed arachnoid cyst on 
the pontocerebellar right side. At 12 years old, she weighed 34 kg (-1.2 SD) and her length was 138 cm 
(-2.1 SD), and presented dysmetria and scoliosis. She showed bradypsychia, clumsiness and 
fatigability, and was unable to read and write or made simple maths calculus properly, but not showed 
clear ataxia, muscle weakness or pyramidal affectation. Electromyogram (EMG) showed a myopathic 
pattern. Cardiologic ultrasonography and heart MRI showed hypertrophic concentric non obstructive 
cardiomyopathy, mostly in septum and left ventricle. Systolic and diastolic functions were normal. 
Muscle histochemistry showed numerous ragged-red fibers (RRF), and MRC analysis evidenced a 
combined deficiency of complexes I, III and IV. The mtDNA molecular analysis showed neither 
deletions nor depletion, and whole mtDNA sequencing revealed known polymorphisms corresponding 
to the Caucasian haplogroup H1c without the presence of pathological variants. Ophthalmologic 
studies and blood testing for liver, kidney and thyroid function were normal, as well as coagulation 
studies and CK levels. However, she had metabolic acidosis (HCO3- 17 mEq/l, normal >24 mEq/l), 
with elevated plasma lactic acid level (6.4 mM, normal < 2.30 mM), lactate/pyruvate ratio (36, normal 
<20), alanine (998 M, normal 170-430M) and homocysteine (23 M, normal 4.0-12.3M). By 
contrast, the level of vitamin B12 was low (143 pg/ml, normal 222-753 pg/ml) while folic acid was 
normal (3.33 ng/ml, normal 2.61-13.6 ng/ml). Studies of CSF showed normal cytochemistry, lactic 
acid, aminoacids, neurotransmitter and 5-MTHF levels. She was treated by L-carnitine, CoQ10, vitamin 
C, vitamin B2, folic acid (vitamin B9), thiamine (vitamin B1), pyridoxine (vitamin B6), and cobalamin 
(vitamin B12). Later, the levels of vitamin B12 and homocysteine were normalized, but 
hyperlactacidemia persisted (ranging 2.4-6.8 mM). Her clinical condition also improved (she weighted 
43.5 Kg (-0.9 SD) and her length was 149 cm (-1.6 SD) and cardiomyopathy was controlled (maximal 
left ventricle wall was 18mm, posterior and lateral, and right ventricle was less affected and systolic 
function was normal). She received also scholar support. 
 Currently, at 19 years old, she presents effort dyspnoea, frequent palpebral eye tics that worsen 
when she is nervous, and she is able to read and count from 1 to 20. Cardiac evaluation showed 
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functional limitation to exercise with early tachycardia, and cardiac ultrasonography showed 
hypertrophic concentric left ventricle (12 mm), while systolic and diastolic function were normal. In 
ophthalmological examination, she showed a distance visual acuity without correction of 20/40 and 
20/30 in right and left eye respectively, and orthophoria in primary position. The fundoscopy exam 
showed papillary pallor in both eyes indicating the she had bilateral partial papillary atrophy. OCT 
showed thinning of macular ganglion cell layer and thinning of macular and peripapillary RNLF in left 
eye, while it was unable to measure in the right eye because palpebral tics and poor collaboration.    
 Patient 3 (Pt3) is the only child of healthy non-consanguineous parents from Germany. She was 
born at term after regular pregnancy and delivery. During the first days of life, she presented with 
metabolic acidosis followed by complete resolution. She could sit at 6 months and walk at 16 months, 
but language was slightly delayed with first words at 2 years. She attended regular school till the age 
of 14 years despite some learning difficulties; since 14 years she needed scholar support. A muscle 
biopsy performed when she was 6 months old showed respiratory chain complexes I and IV deficiency 
whereas histology was normal. During childhood she suffered fatigability and clumsiness without any 
other symptom. At 11 years, after a syncope, heart ultrasonography showed hypertrophic concentric 
non-obstructive cardiomyopathy, mostly affecting septum and left ventricle. Systolic and diastolic 
functions were normal. A treatment by beta blockers agents was started. At 14 years, she started to 
present short lasting focal epileptic seizures characterized by myoclonic arms movements followed by 
loss of contact and tonic head deviation. Seizures were initially refractory to antiepileptic treatment 
(levetiracetam, 2000 mg/day) with persistence of daily episodes. 
 Currently, at 16 years of age, seizures have a frequency of one per month under levetiracetam 
(2000 mg/day) and clobazam (20 mg/day). Neurological exam is normal. EEG showed a slow 
background activity with theta/delta waves and right frontotemporal spikes. She presents fatigability 
and clumsiness. She is treated by L-carnitine (2.5 g/day), idebenone (135 mg/day), nadolol (60 
mg/day), levetiracetam (2000 mg/day) and clobazam (20 mg/day).  
10 
 
 Brain MRI showed a bilateral signal hyperintensity involving dentate nuclei and a pre-central 
cortex. Ophthalmological exam detected a slight bilateral optic atrophy with normal right and 8/10 left 
visual acuity. Fundoscopy revealed temporal papillary pallor predominating on left eye, and OCT 
showed thinning of peripapillary RNLF in both eyes. Laboratory examinations showed 
hyperlactacidemia (lactate 7.8 mM, normal 1.0-1.5 mM), and elevated plasma alanine (822 M, 
normal 221-481M).  
Genetic analysis 
 The aforementioned analytic pipeline of WES data, enabling us to prioritize variants in genes 
that were rare and were predicted to be deleterious. We confirmed the presence of two homozygous 
missense mutations in Pt1 and Pt2: p.R504C (NM_001123226:c.1510C>T) and p.V557M 
(c.1669G>A,) in the MTO1 (Mitochondrial tRNA translation optimization 1) gene. The mutations 
segregate with the disease in both families through a recessive inheritance pattern. The parents of both 
families are heterozygous for the mutations and the healthy sister of the family 1 is wild type (Fig. 2a). 
In order to discard a common ancestor between these two families, we studied the rare variants (allele 
frequency below 0.01 or new) identified by WES in chromosome 6. Of around 500 variants, only 5 
were present in both patients: two homozygous in MTO1 gene and three heterozygous in different 
genes. These data make it unlikely that both families have a recent common ancestor. In Pt3 was only 
detected the homozygous p.R504C variation in MTO1 gene. The mother is heterozygous for this 
variant but DNA from the father is not available (Fig. 2a). A heterozygous MTO1 deletion affecting 
the other allele could be excluded by NGS. The p.R504C mutation was ascribed as "likely pathogenic" 
by using well established in-silico tools of pathogenesis prediction (SIFT, PolyPhen2, MutPrep and 
Mutation Taster) (Table 1). It is located in a conserved region of MTO1 gene (Fig. 2b) and the 
aminoacid residue is conserved from Homo sapiens to Saccharomyces cerevisiae (Fig. 2c). However, 






We describe three adolescent patients from three unrelated families (Table 2) presenting with defects 
of MRC activities, encephalopathy (intellectual disability), hypertrophic cardiomyopathy diagnosed 
during later infancy or childhood, lactic acidosis, and optic nerve atrophy developed in adolescence, 
suggesting a mitochondrial disease (Table 2). In addition, two of them had epilepsy. However, 
molecular mtDNA analysis in the patients ruled out depletion, rearrangements or known or putative 
pathogenic mutations. Using WES, we identified two homozygous mutations in the nuclear-encoded 
gene MTO1 (mitochondrial tRNA translation optimization 1) (Table 1) that are located inside of 
GidAad3 domain of the protein (Fig. 2b). GidA is the eubacterial ortholog of MTO1, and the GidA 
associated domain 3 (GidAad3) has been suggested to be implicated in binding of FAD (Flavin 
Adenine Dinucleotide) and the D-stem of tRNA (7), and to be responsible for the interaction with 
GTPBP3 protein (8). The first missense mutation (R504C), founded in the three patients, changes a 
conserved arginine to cysteine (Fig. 2), and it is not described in any genomic database (2016-5): 
1000G, EVS and ExAC Browser. The R504C mutation is described as "likely pathogenic" by in-silico 
analysis software (SIFT, PolyPhen2, MutPrep and Mutation Taster) (Table 1), and the aminoacid is 
evolutionarily conserved among species (Fig. 2c). Furthermore, we identified the R504 of Homo 
sapiens MTO1 as equivalent to R434 of Aquifex aeolicus GidA, which is located in FAD binding site 
(N1 atom of R434 binds to the flavin N3 and O4 atoms by hydrogen bond) (7). The second variant 
(V577M), that was only founded in Pt1 and Pt2, is described in genomic databases (rs139608228) as 
very rare variant (allele frequency of 0.001504) and as "polymorphism" by in-silico analysis (Table 1). 
Furthermore, the aminoacid V577 is not conserved among species (Fig. 2c). 
 The mutation R504C has been recently reported (9) in two siblings who presented a 
multisystemic disorder associating optic atrophy, cardiomyopathy, cognitive disability and epileptic 
seizures. These patients also carried a homoplasmic mutation (m.593T>G) in the mitochondrial 
tRNAPhe that could act synergistically to worsen the disease (9). The phenotype of these two siblings is 
almost identical to the shown by our three patients (cardiomyopathy, lactic acidosis, encephalopathy, 
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defects of MRC activities, optic atrophy and epilepsy), but the mtDNA sequence in Pt1 and Pt2 
excluded the presence of any mtDNA pathological mutation. Therefore, it is unlikely that the mutation 
in the mitochondrial tRNAPhe (that is not present in our patients) or the variant V557M in MTO1 gene 
(that is not present in the two siblings and Pt3) may contribute to the core clinical phenotype. As the 
two siblings (9) and our three patients developed optic nerve atrophy during adolescence or adulthood, 
this phenotype could considered as characteristic of this mutation (R504C), in contrast to epilepsy, 
since only one of the two siblings and Pt1 and Pt3 have epilepsy. Accordingly, the core phenotype 
associated to R504C mutation in MTO1 gene is cardiomyopathy, lactic acidosis, encephalopathy with 
optic neuropathy and combined OXPHOS deficiency, being secondary phenotype epilepsy. Based on 
the association of the clinical features and biochemical abnormalities of these five patients, we suggest 
that they form a new clinical subgroup of combined OXPHOS deficiency 10 (MIM#614702; 
COXPD10, also "cardiomyopathy, infantile hypertrophic mitochondrial, and lactic acidosis"), with 
optic neuropathy and encephalopathy, or ONCE syndrome (acronym for Optic Neuropathy, 
Cardiomyopathy, and Encephalopathy with lactic acidosis and combined OXPHOS deficiency). And 
the R504C mutation in MTO1 gene is the responsible for this syndrome. 
 So far, only 11 mutations, 9 missense and 2 frameshift, in the MTO1 gene have been described 
in 16 patients (Table 3). Cardiomyopathy were diagnosed in 14 patients, from which 7 died in neonatal 
or infancy period and 7 patients have survived until adolescence or adulthood. The phenotype and 
severity of the disease are partially correlated with the onset and clinical presentation. Thus, patients 
with neonatal-onset deceased during the first year of live, while patients with onset in infancy were 
able to survive to the adolescence and adulthood. Others phenotypes such as intellectual disability, 
epileptic seizures and optic nerve atrophy seen to be associated with long term evolution. 
 The patients Pt1 and Pt2 had other metabolic deficiencies that have not been reported before in 
patients with MTO1 gene mutations. Thus, Pt1 had cerebral folate deficiency without abnormalities in 
brain MRI, unlike it has been demonstrated in other mitochondrial syndromes (10). Supplementation 
with folinic acid normalized the biochemical parameters in CSF, as described in cerebral folate 
13 
 
deficiency syndrome (11), but without major changes in her cognitive status. On the other hand, Pt2 
showed hyperhomocysteinemia due to vitamin B12 deficiency, which were normalized after vitamin 
B12 treatment. Cerebral folate deficiency or Vitamin B12 chronic deficiency could cause several 
neurological problems and mental deterioration that could contribute to worsen the phenotype. Thus, 
CSF folate levels and vitamin B12 levels should be investigated in patients with MTO1 mutations in 
order to define the phenotypic spectrum. 
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Fig. 1. Ophthalmological finding using 3D-OCT (Topcon model 2000). (a) The temporal papillary 
pallor in both eyes of Pt1 is shown. (b) Macular ganglion cell complex analysis by OCT scan in both 
eyes of Pt1 is shown. All retinal fovea sublayer (retinal nerve fiber layer (RNFL), ganglion cell layer 
(GCL)) showed significant thinning. The average thickness is compared to the normative data and 
displayed according to color. (c) The thinning of peripapillary RNFL in both eyes of Pt1 is shown. 
 
 
Fig. 2. Genetic and functional analysis. (a) Family pedigrees showing segregation of R504C (C/T) and 
V557M (G/A) mutations in MTO1. (b) Schematic representation of human MTO1 showing the 
position of R504C (red) and V557M (green) mutations, and the GidAad3 domain. (c) Multiple 
sequence alignment of MTO1 protein region surrounding the R504 (red) and V557 (green) in various 








WES candidate genes  
Candidate genes after filtering and prioritization 
Chr Positiona SNP Ref Status Gene Codon Change MAFb 
6 74191892 New C Homc MTO1d CGC=>TGC R504C  
6 74192255 rs139608228 G Hom MTO1 GTG=>ATG V557M 0.0015 
"In silico" analysis   
Gene Change SIFT PolyPhen-2 Mutation Taster MutPred 
MTO1c R504C Damaging Probably damaging Disease causing Disease-associated 
MTO1 V557M Tolerated Benign Polymorphism Neutral 














Patients with mutations in MTO1 gene 
Characteristics Pt1 Pt2 Pt3 
Sex Male Female Female 
Age  16y 19y 16y 
Onset  Infancy Childhood Childhood 
Consanguinity No No No 
Cardiomyopathy 22m 12y 11y 
Optic Neuropathy 7y 19y 16y 
Encephalopathy 2y 8y 2y 
Lactic acidosis yes yes yes 
OXPHOS deficiency 2y (I+IV) 12y (I+III+IV) 14y (I+IV) 
Epilepsy 6y No 14y 
EEG 6y: a 8y: n 16y: a 
Brain MRI 2y: n, 11y: n 8y: a1 16y: a2 
Folic acid deficiency 11y No No 
Vitamin B12 deficiency No 12y No 
EMG  nd 12y: mp nd 
Genetic study R504C3+V557M3 R504C3+V557M3  R504C3  
y: year; m: month; nd: not determined; n: normal; a: altered; mp: myopathic pattern  
EEG: electroencephalography; MRI: magnetic resonance images; EMG: electromyography 
1Arachnoid cyst on the pontocerebellar right side 












Selected MTO1a Pathogenic Variants 
Amino Acid Change Mutation type  Reference 
p.R660Lfs*8 Frameshift (NMDb) 
Ghezzi et al [2012] 
p.A468T Missense 
p.G59A Missense 
Vasta et al [2012] 
p.T308A Missense 
p.R517H Missense 
Baruffini et al [2013] 
p.T411I Missense 
p.G211Dfs*3 Frameshift (NMD) 
Taylor et al [2014] p.V41G Missense 
p.H256R Missense 
p.I408F Missense Tischner et al [2015] 
p.R504C Missense Charif et al [2015] 
aRefSeq NM_001123226.1 
bNMD, nonsense-mediated mRNA decay 
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